Mersana Therapeutics Future Growth
Future criteria checks 2/6
Mersana Therapeutics is forecast to grow earnings and revenue by 6.6% and 33.4% per annum respectively. EPS is expected to grow by 3.8% per annum. Return on equity is forecast to be -1761.1% in 3 years.
Key information
6.6%
Earnings growth rate
3.8%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 33.4% |
| Future return on equity | -1,761.1% |
| Analyst coverage | Good |
| Last updated | 18 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 46 | -108 | -74 | -78 | 9 |
| 12/31/2025 | 29 | -92 | -68 | -74 | 10 |
| 12/31/2024 | 32 | -75 | -62 | -71 | 10 |
| 9/30/2024 | 35 | -75 | -96 | -95 | N/A |
| 6/30/2024 | 30 | -105 | -134 | -133 | N/A |
| 3/31/2024 | 38 | -135 | -174 | -173 | N/A |
| 12/31/2023 | 37 | -172 | -171 | -169 | N/A |
| 9/30/2023 | 41 | -197 | -191 | -188 | N/A |
| 6/30/2023 | 39 | -215 | -90 | -87 | N/A |
| 3/31/2023 | 32 | -213 | -73 | -70 | N/A |
| 12/31/2022 | 27 | -204 | -52 | -49 | N/A |
| 9/30/2022 | 12 | -208 | -42 | -41 | N/A |
| 6/30/2022 | 6 | -194 | -132 | -131 | N/A |
| 3/31/2022 | 2 | -183 | -122 | -121 | N/A |
| 12/31/2021 | 0 | -170 | -141 | -140 | N/A |
| 9/30/2021 | 0 | -150 | -116 | -115 | N/A |
| 6/30/2021 | 0 | -127 | -100 | -99 | N/A |
| 3/31/2021 | 1 | -106 | -81 | -80 | N/A |
| 12/31/2020 | 1 | -88 | -75 | -75 | N/A |
| 9/30/2020 | 1 | -75 | -70 | -70 | N/A |
| 6/30/2020 | 2 | -70 | -66 | -66 | N/A |
| 3/31/2020 | 1 | -67 | -65 | -64 | N/A |
| 12/31/2019 | 42 | -28 | -68 | -68 | N/A |
| 9/30/2019 | 43 | -34 | -72 | -71 | N/A |
| 6/30/2019 | 45 | -35 | -66 | -65 | N/A |
| 3/31/2019 | 49 | -30 | -64 | -63 | N/A |
| 12/31/2018 | 11 | -64 | -57 | -55 | N/A |
| 9/30/2018 | 13 | -56 | -52 | -50 | N/A |
| 6/30/2018 | 17 | -46 | N/A | -51 | N/A |
| 3/31/2018 | 16 | -43 | N/A | -49 | N/A |
| 12/31/2017 | 18 | -39 | N/A | -43 | N/A |
| 9/30/2017 | 26 | -23 | N/A | -19 | N/A |
| 6/30/2017 | 23 | -22 | N/A | -12 | N/A |
| 3/31/2017 | 26 | -16 | N/A | -11 | N/A |
| 12/31/2016 | 25 | -14 | N/A | 32 | N/A |
| 12/31/2015 | 10 | -16 | N/A | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0M4 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 0M4 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 0M4 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 0M4's revenue (33.4% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 0M4's revenue (33.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0M4 is forecast to be unprofitable in 3 years.